Echo IQ has submitted an application to the US FDA for market clearance of its AI-backed decision support tool, EchoSolv™, which assists in detecting aortic stenosis.
The company anticipates that FDA clearance will significantly accelerate commercial uptake by broadening the addressable market and creating financial incentives for US hospitals to adopt the technology.
ASX Code: EIQ